• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Catheter Precision Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    11/21/25 4:15:57 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care
    Get the next $VTAK alert in real time by email
    vtak20251119_8k.htm
    false 0001716621 0001716621 2025-11-17 2025-11-17
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
    ___________________
     
    FORM 8-K
    ___________________
     
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported):
    November 17, 2025
    ___________________
     
    Catheter Precision, Inc.
    (Exact name of registrant as specified in its charter)
    ___________________
     
    Delaware
     
    001-38677
     
    38-3661826
    (State or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)
     
    1670 Highway 160 West
    Suite 205
    Fort Mill, SC 29708
    (Address of principal executive offices, including zip code)
     
    (973) 691-2000
    (Registrant’s telephone number, including area code)
     
    N/A
    (Former name or former address, if changed since last report.)
    ___________________
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.0001 per share
    VTAK
    NYSE American
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     

     
     

     
     
    Item 1.02. Termination of a Material Definitive Agreement. 
     
    On November 17, 2025, Catheter Precision, Inc. (the “Company”) delivered notice to terminate its At-Market-Offering Agreement (the “ATM Agreement”), dated as of May 19, 2025, with Ladenburg Thalmann & Co. Inc. (the “Agent”) providing for the Company’s “at‑the‑market” equity offering program (the “ATM Program”), to be effective as of November 24, 2025. Pursuant to the ATM Agreement and the prospectus supplements filed for the ATM Program, the Company could offer and sell, from time to time through the Agent, shares of its common stock, par value $0.0001 per share (“common stock”), having an aggregate offering price of up to $4.3 million. The Company is not subject to any termination penalties related to the termination of the ATM Agreement. Prior to the termination notice, the Company sold approximately $4.0 million of shares of common stock under the ATM Program.
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
       
    CATHETER PRECISION, INC.
     
             
    Date:
    November 21, 2025
    By:
    /s/ Philip Anderson
     
         
    Philip Anderson
     
         
    Chief Financial Officer
     
     
     
    Get the next $VTAK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTAK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Catheter Precision Announces Strategic Sale of Non-Core Assets to Strengthen Balance Sheet and Accelerate Electrophysiology Growth

    FORT MILL, S.C., Feb. 19, 2026 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (NYSE:VTAK), a leader in advanced electrophysiology solutions, today announced it has entered into a definitive agreement to divest its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer. Following a comprehensive portfolio review, the Company determined that monetizing these non-core assets enhances capital efficiency and sharpens focus on its high-growth electrophysiology platform. Strategic Rationale Focus our capital allocation on core cardiac arrhythmia technologiesStrengthened balance sheetSimplified operating structure with enhanced strategic clarit

    2/19/26 8:15:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    VTAK Acquires 19.98% Strategic Stake in AI-Enabled Aviation Company Fly Flyte, Inc.

    Immediate Exposure to Revenue-Generating, Asset-Backed Regional Air Mobility Business Positioned Ahead of Anticipated Future Industry-wide eVTOL Commercialization Strategic Investment Expands Capital Allocation into High-Growth Infrastructure with Scalable Fleet Expansion and Long-Term Equity Upside Fort Mill, S.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced a strategic minority investment in Fly Flyte, Inc. ("Flyte"), an FAA-certified regional aviation operator utilizing AI-enabled operations and a growing fleet of Cirrus Vision Jets. Flyte conducts its flight operations through its wholly owned subsidiary, Ponderosa Air, LLC (FAA Air Carrie

    2/17/26 7:45:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    SEC Filings

    View All

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    2/12/26 4:15:59 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    2/6/26 5:25:30 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    11/21/25 4:15:57 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman of the Board and CEO Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    2/18/26 4:16:13 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chairman of the Board and CEO Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    1/20/26 4:20:00 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Director Caruso James Joseph converted options into 41 shares, increasing direct ownership by 456% to 50 units (SEC Form 4)

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    12/8/25 4:54:19 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/13/24 11:14:58 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

    SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

    10/30/24 5:26:20 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Leadership Updates

    Live Leadership Updates

    View All

    Catheter Precision, Inc. Announces New Chief Financial Officer

    FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

    1/7/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

    FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

    1/22/24 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Financials

    Live finance-specific insights

    View All

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results

    FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include: Commercial Endeavors Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues to build a strong pipeline.After the close of the March quarter, the Company announced its acquisition of the assets of Cardionomics, Inc. through its newly formed, 82% owned subsidiary, Cardionomix, Inc. Th

    5/14/25 4:30:00 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results

    FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024. Highlights of 2024 and the fourth quarter include: New Chief Commercial Officer (CCO) joined in Q2, 2024.Replaced the majority of our prior sales team with new salespeople selected by our new CCO and our CEO. Training was completed in Q3, 2024.The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter through the end of the year, to both new and repeat customers.The number of hospitals, inclu

    3/28/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care